Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial.
CONCLUSIONS: TF-TAVI using the SAPIEN 3 THV in patients at intermediate risk for surgery is associated with a very low risk of death and complications, including new pacemakers and paravalvular leaks. Although compelling, these initial results are being confirmed in larger global studies before expanding the indications for TAVI in severe aortic stenosis.
PMID: 27290682 [PubMed - in process]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
More News: Anesthesia | Anesthesiology | Aortic Stenosis | Cardiology | Cardiovascular & Thoracic Surgery | CT Scan | Electrocardiogram | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Stroke | Study